# Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

> **NCT00479856** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 9 (actual)

## Conditions studied

- Relapsed Breast Cancer
- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Capecitabine
- **DRUG:** Docetaxel
- **DRUG:** nab-Paclitaxel

## Key facts

- **NCT ID:** NCT00479856
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2009-09
- **Final completion:** 2010-03
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study was terminated due to difficulty in identifying eligible subjects
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479856, "Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00479856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*